{"id":"W3212274217","doi":"10.1136/jitc-2021-sitc2021.374","title":"374 A phase IB trial of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors","year":2021,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Sanofi","keywords":"Pembrolizumab; Aflibercept; Medicine; Oncology; Internal medicine; Cancer; Bevacizumab; Immunotherapy; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002005294,0.0002500878,0.0006296302,0.0001277027,0.00005550737,0.00002637896,0.00007377224,0.0001322861,0.00004086946],"category_scores_gemma":[0.0001831803,0.0002087789,0.0001165818,0.0003248025,0.0003141531,0.000164187,0.00002853302,0.000219072,0.000002283406],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001351137,"about_ca_system_score_gemma":0.0009582291,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009225078,"about_ca_topic_score_gemma":0.00005431468,"domain_scores_codex":[0.9981542,0.00005915497,0.000605423,0.0003974261,0.0004527041,0.0003310879],"domain_scores_gemma":[0.9988559,0.00003059549,0.0002382453,0.0003729157,0.0001555826,0.0003468001],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6637543,0.007362552,0.07087082,0.001969299,0.001403776,0.00159183,0.006498393,0.0002783503,0.191863,0.0002138407,0.002491782,0.05170208],"study_design_scores_gemma":[0.4736041,0.005406834,0.4152679,0.001591241,0.0002519339,0.0001705164,0.0005247191,0.00007502394,0.09821729,0.0001308777,0.00414113,0.0006184206],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9975437,0.0005818963,0.000004401092,0.0003630329,0.0002358143,0.0006689202,0.00003090154,0.00003263995,0.0005386813],"genre_scores_gemma":[0.9985316,0.0001047224,0.0004676798,0.0003237866,0.00007825277,0.00002688366,0.0001079054,0.00003739672,0.0003217266],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3443971,"threshold_uncertainty_score":0.8513758,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01062840677381271,"score_gpt":0.2660235208790911,"score_spread":0.2553951141052784,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}